Repligen Corporation (RGEN): Price and Financial Metrics
Repligen Corporation (RGEN)
Today's Latest Price: $176.25 USD
Updated Oct 26 9:36am
Add RGEN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
RGEN Stock Summary
- With a one year PEG ratio of 2,928.9, Repligen Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.59% of US stocks.
- RGEN's current price/earnings ratio is 291.47, which is higher than 97.47% of US stocks with positive earnings.
- The price/operating cash flow metric for Repligen Corp is higher than 97.26% of stocks in our set with a positive cash flow.
- Stocks that are quantitatively similar to RGEN, based on their financial statements, market capitalization, and price volatility, are TDOC, MLAB, PRAH, PAYC, and AKAM.
- Visit RGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.repligen.com.
RGEN Stock Price Chart Interactive Chart >
RGEN Price/Volume Stats
| Current price | $176.25 | 52-week high | $177.92 |
| Prev. close | $176.25 | 52-week low | $76.85 |
| Day low | $174.95 | Volume | 5,689 |
| Day high | $176.27 | Avg. volume | 518,889 |
| 50-day MA | $154.92 | Dividend yield | N/A |
| 200-day MA | $124.50 | Market Cap | 9.25B |
Repligen Corporation (RGEN) Company Bio
Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
RGEN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $176.25 | $18.31 | -90% |
We started the process of determining a valid price forecast for Repligen Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Repligen Corp ranked in the 12th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Repligen Corp, consider:
- In the past 5.38 years, Repligen Corp has a compound free cash flow growth rate of 0.25%; that's higher than 61.59% of free cash flow generating stocks in the Healthcare sector.
- 97% of the company's capital comes from equity, which is greater than 89.36% of stocks in our cash flow based forecasting set.
- The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.6% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -90% |
| 1% | -90% |
| 2% | -90% |
| 3% | -90% |
| 4% | -89% |
| 5% | -89% |
Want more companies with a valuation profile/forecast similar to that of Repligen Corp? See BLFS, LGND, VAR, ELAN, and PCRX.
Loading social stream, please wait...